Attenuated/Inactivated/Live and Vectored Vaccines
A section of Vaccines (ISSN 2076-393X).
Section Information
Aims
The aim of the section “Attenuated/Inactivated/Live and Vectored” is to describe current experimental and conceptual advances in the design, development, processing and manufacturing of safe, efficient and cost-effective vaccines.
Scope
We will consider manuscripts investigating cell culture produced attenuated/inactivated/live and particularly vectored vaccines design, processing, manufacturing and formulation for global delivery. Studies on mechanism of protection and immunological responses to this class of candidate vaccines as well as evaluation of safety, immunogenicity and protection in animals and humans will be considered. Advances in formulation to support non-invasive delivery modes of attenuated/inactivated/live and vectored vaccines to improve their safety and delivery contributing to broader availability remain important quality attributes of this class of vaccines. The section will publish different types of manuscripts, including short definitive reports, full-size papers, and reviews. All submissions will undergo rigorous peer review.
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Innovations in Vaccine Technology (Deadline: 30 November 2024)
- Utilization of Non-human Viruses as Recombinant Vector Vaccines against Newly Emerging Human Viral Diseases (Deadline: 31 January 2025)
- Viral Vector-Based Vaccines and Therapeutics (Deadline: 31 January 2025)
- Nanoparticle Based Vaccines (Deadline: 28 February 2025)
- Virus-Like Particle Vaccine Development (Deadline: 28 February 2025)
- Bioengineering in Vaccine Design and Delivery (Deadline: 1 March 2025)
- (Virus-Like) Particles as Platforms for Vaccine Delivery and Modulation of Immune Cell Function (Deadline: 31 May 2025)
- State-of-the-Art Vaccine Design (Deadline: 30 June 2025)
- Strategies of Viral Vectors for Vaccine Development (Deadline: 31 August 2025)
